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Erk1/2 signaling degradationThe protease-activated receptor 1 (PAR1) is a G-protein-coupled receptor that is irreversibly activated by either
thrombinormetalloprotease 1. Due this irrevocable activation, activated internalization and degradation are crit-
ical for PAR1 signaling termination. Prohibitin (PHB) is an evolutionarily conserved, ubiquitously expressed,
pleiotropic protein and belongs to the stomatin/prohibitin/ﬂotillin/HﬂK/C (SPFH) domain family. In a previous
study, we found that PHB localized on the plateletmembrane and participated in PAR1-mediated human platelet
aggregation, suggesting that PHB likely regulates the signaling of PAR1. Unfortunately, PHB's exact function in
PAR1 internalization and degradation is unclear. In the current study, ﬂow cytometry revealed that PHB
expressed on the surface of endothelial cells (HUVECs) but not cancer cells (MDA-MB-231). Further confocalmi-
croscopy revealed that PHB dynamically associates with PAR1 in a time-dependent manner following induction
with PAR1-activated peptide (PAR1-AP), though differently between HUVECs andMDA-MB-231 cells. Depletion
of PHB by RNA interference signiﬁcantly inhibited PAR1 activated internalization and led to sustained Erk1/2
phosphorylation in the HUVECs; however, a similar effect was not observed in MDA-MB-231 cells. For both
the endothelial and cancel cells, PHB repressed PAR1 degradation, while knockdown of PHB led to increased
PAR1 degradation, and PHB overexpression inhibited PAR1 degradation. These results suggest that persistent
PAR1 signaling due to the absence of membrane PHB and decreased PAR1 degradation caused by the upregula-
tion of intracellular PHB in cancer cells (such as MDA-MB-231 cells) may render cells highly invasive. As such,
PHB may be a novel target in future anti-cancer therapeutics, or in more reﬁned cancer malignancy diagnostics.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Prohibitin (PHB or PHB1), a 32 kDa protein, is ubiquitously
expressed and evolutionary conserved across organisms from yeast to
humans, playing roles in the regulation and maintenance of mitochon-
drial functions [1]. Nuclear PHBmeanwhile is engaged in several impor-
tant transcriptional regulations, mainly being associated with cell-cycle
progression and apoptosis [2]. A number of reports over the past few
years have highlighted the function of plasma membrane PHB. Inology, The Chinese Academy of
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PHBs functions as a binding site for theVi capsular polysaccharide of Sal-
monella typhi, the causative agent of typhoid fever in humans [3]. Other
studies report that themembrane PHBmay facilitate the entry of DENV-
2 (the causative agent of the most common mosquito-borne viral dis-
ease in human) into insect cells [4].Meanwhile, PHB engaged in cell sur-
face Raf-MEK-ERK signaling and human platelet PAR1 signaling [5,6].
The relationship between PHB and cancer has gained increased scrutiny
among researchers in recent years. Several studies on various cancer
cells have found elevated protein levels of PHB [7,8]; however, the
role of PHB in cancer cell remains controversial.
PAR1, the protease activated receptor 1, also known as the thrombin
receptor, which belongs to the G-protein-coupled receptor family is
highly expressed in a variety of cell types, including endothelial cells,
platelets, monocytes, neurons and cancer cells. Consequently, PAR1
plays important roles in thrombosis, angiogenesis, inﬂammation and
metastasis [9–11]. PAR1 is activated in a unique proteolytic manner,
wherein thrombin binds to and cleaves the extracellular N-terminal
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PAR1 [12]. Similarly, PAR1 can be activated directly via the six-residue
peptide (S/TFLLRN) that corresponds to the tethered ligand of PAR1
[13]. At this juncture, the tethered ligand cannot diffuse away, leading
to activated PAR1 becoming internalized and sorted into the lysosome,
resulting in its degradation. Recent investigations have demonstrated
that irreversibly and proteolytically-activated PAR1 was internalized
through a clathrin-and dynamin-dependent pathway and sorted to ly-
sosome for degradation [14]. Meanwhile, experimental evidences
have shown that several functional molecules participate in the regula-
tion of PAR1 internalization and degradation, including the clathrin
adaptor AP-2 [15], epsin-1 [16], ALIX [17] and sorting nexin 1 (SNX1)
[18]. Additionally, constitutive internalization also plays an important
role in PAR1-related functions. Unactivated PAR1 constantly cycles be-
tween the cell surface and the intracellular stores, which provides a
pool that replenishes the cell surface after PAR1 activation and leads
to the rapid resensitization of PAR1 signaling independent of de novo re-
ceptor synthesis [19].
The precise regulatorymechanismsunderlying PAR1 signal termina-
tion—including internalization and degradation—are critical in the PAR1
response present inmany physiological and pathological processes. Un-
fortunately, some aspects of the internalization and degradation of
PAR1 remain unclear, especially regarding the relationship between
PHB and PAR1 internalization and degradation. In a recent study, we
found that PHB is localized on the platelet membrane and also involved
in PAR1-mediated human platelet aggregation, indicating that PHB is a
previously unknown cofactor of the PAR1-related signaling pathway
[5]. For platelets which were anuclear cells, the activation of PAR1
only occurred a single time during the lifespan of platelets, suggesting
that many other important events of PAR1, e.g., internalization and deg-
radation are not carried out in platelets. Previous evidence, however,
found that PAR1 mainly expressed in primary cells and cancer cells
[20], and likewise that PHB or PAR1 is involved the proliferation and
metastasis of carcinoma cells [21]. However, there is a lack of clear evi-
dence highlighting the different relationship between cancerous cells
and either PHB or PAR1, and such informationmay prove useful in ﬁnd-
ing ways to overcome cancerous cell growth.
In this study, we selected two nuclear cell lines to serve as models:
normal endothelial cells (HUVECs) and breast cancer cells (MDA-MB-
231 cells). Our analyses of these cells showed that PHB participated in
PAR1-activated internalization, Erk1/2 phosphorylation and PAR1 deg-
radation induced by PAR1-AP in HUVECs. Meanwhile, the regulation
of these processes was aberrant in MDA-MB-231 cells; showing that
PHB did not regulate PAR1 activated internalization or Erk1/2 phos-
phorylation, but that the increased expression of PHB in cancer cells
inhibited PAR1 degradation. Together, these differing properties may
be responsible for the invasive capacity of different types of cancer
cells, making them key targets for further research into the activities
and characterization of cancerous cells.
2. Materials and methods
2.1. Materials
The PAR1-activating peptide PAR1-AP (TFLLRN) was synthesized by
GL Biochem (Shanghai, China). The anti-PAR1 monoclonal antibody
(ATAP2), mitochondrial marker antibody, anti-COXIV and horseradish
peroxidase (HRP)-conjugated secondary antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA), while the anti-
PHB polyclonal antibodies were purchased from R&D Systems
(AF3470) (Minneapolis, MN, USA) and Santa Cruz Biotechnology (H-
80) (Santa Cruz, CA, USA), and the monoclonal antibody was obtained
from Neomarkers (Fremont, CA, USA). The anti-phospho-p44/42
MAPK (Erk1/2) (Thr202/Tyr204) antibody and the anti-p44/42 MAPK
(Erk1/2) antibody were obtained from Cell Signaling Technology, Inc.
(Danvers, MA, USA). The anti-EEA1, anti-LAMP1, anti-Histone H3 rabbitpolyclonal antibodies and themousemonoclonalM2 anti-Flag antibody
were purchased from Sigma (St. Louis, MO, USA). The Alexa 488-, Alexa
594- and Alexa 647-conjugated goat anti-rabbit, goat anti-mouse and
donkey anti-goat antibodies were respectively obtained from
Invitrogen (Carlsbad, CA, USA). Cell mitochondria isolation and nuclear
protein extraction kits were purchased from the Beyotime Institute of
Biotechnology (Wuhan, Hubei, China) and the Matrigel Basement
Membrane Matrix was purchased from Becton Dickinson (BD) Biosci-
ences (San Jose, CA, USA). All other reagents were purchased from
Sigma (St. Louis, MO, USA). Protein concentrations were determined
using a protein assay kit (Bio-Rad, Hercules, CA, USA) with BSA as a
standard.
2.2. Calcium mobilization
To measure cytoplasmic Ca2+, cells were dissociated using enzyme-
free cell dissociation buffer (Invitrogen) and then incubated for 30 min
with 5 μM ﬂuo-3 AM in a buffer containing 145 mM NaCl, 5 mM KCl,
1 mMMgCl2, 10 mM Hepes, 10 mM glucose and 1% BSA (PH 7.4, adjust
by NaOH at 37 °C). Fluo-3 ﬂuorescence was measured at 37 °C in a
Perkin-Elmer LS-5 ﬂuorimeter at 505 nm excitation and 530 nm emis-
sion. For the cell inhibition assays, cells were pretreated with a mono-
clonal antibody (IV.3) to block anti-FcγRIIA (CD32) and prevent the
nonspeciﬁc actions of the anti-PHB antibody.
2.3. Internalization assay
PAR1 internalization was assessed using the method previously de-
scribed by Chen et al. [16]. In brief, cells were plated in 96-well dishes at
a density of 5 × 103 cells per well and grown overnight. The cells were
washed with PBS, and then incubated in DMEM containing 1 mg/ml
BSA (pH 7.4), and subsequently either treated or not treated with 75
μM PAR1-AP for various times at 37 °C. Cells were then ﬁxed with 4%
paraformaldehyde for 5 min at 4 °C and subsequently incubated with
an anti-PAR1 antibody for 1 h at 25 °C. The cells were then washed,
and incubated with a horseradish peroxidase-conjugated goat anti-
mouse secondary antibody for 1 h at 25 °C. Next, the cells were washed
and incubated with the horseradish peroxidase substrate 3,3′,5,5′-
tetramethylbenzidine (TMB) for 10 min, and equal aliquots were re-
moved to new 96-well dishes. Optical density of the cells was deter-
mined at 450 nm using an Inﬁnite M200 PRO Microplate Reader
(TECAN Company, Switzerland).
2.4. Flow cytometry
The ﬂow cytometry methods used in the present study are similar to
those mentioned in our previous report [5]. In brief, to detect the surface
expression of PAR1 and PHB using immunoﬂuorescence staining, human
umbilical vein epithelial cells (HUVECs) andMDA-MB-231 cells were dis-
sociated using enzyme-free cell dissociation buffer (Invitrogen), and sub-
sequently incubated with the appropriate primary and secondary
antibodies. After washing three times, all samples were analyzed using
a ﬂow cytometer (FACSVantage SE, Becton Dickinson, NJ, USA).
2.5. Confocal microscopy
Confocalmicroscopy analysis was performed according to themeth-
od described by Booden et al. [22]. BothHUVECs andMDA-MB-231 cells
were grown on cover slips in a 24-well tissue culture plate. The cells
were then washed with PBS and incubated with an anti-PAR1 antibody
for 1 h at 4 °C. Cells then were washed three times with PBS and incu-
bated, either with or without the PAR1 agonist at 37 °C for various
times. Finally, cells were ﬁxed, permeabilized, and immunostained
with the appropriate primary and secondary antibodies, and the slides
were observed using a confocalmicroscope (Olympus FV1000, Olympus
Corporation, Tokyo, Japan).
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Washed cells were incubated with the agonist, PAR1-AP, for the in-
dicated times and then washed and lysed with NP-40 buffer (50 mM
Tris, 150 mMNaCl, 0.5% NP-40, 2% BSA and complete protease inhibitor
cocktail, pH 7.4). The lysates were then immunoprecipitated with the
respective primary antibodies, as described in our previous report [5].2.7. Cell culture and transfection
The breast carcinoma MDA-MB-231 cell line was obtained from the
American Type Culture Collection (ATCC) (Manassas, VA, USA) and
maintained in growth media as recommended by the ATCC. HUVECs
were also obtained from the ATCC and cultured in growthmedia as rec-
ommended by the ATCC. The full open-reading frame of the mature
human PHB cDNA, obtained from cDNAs prepared from human placen-
ta, was subcloned into the pCMV-Myc vector at the EcoRI and HindIII
sites; a Flag-tag was included at the N-terminus of the protein. For tran-
sient transfection, cells were placed in 24-well tissue culture plates and
then transfected with 4 μg of plasmids (pCMV-Myc vector or pCMV-
Myc-Flag-PHB) for 48 h, using either the HiPerFect transfection reagent
(Qiagen, Valencia, CA, USA) or FuGENE 6 transfect reagent (Promega,
Madison, WI, USA). For RNA interference (RNAi) experiments, cells
were cultured to 40–50% conﬂuence prior to transfection. Small inter-
fering RNAs targeted against PHB (siPHB) or a negative control (siCtrl)
were transfected into cells using the Lipofectamine RNAiMax Transfec-
tion reagent (Invitrogen, Carlsbad CA, USA). The siPHB (5′-CAGAAAUCFig. 1. PHB is not involved in PAR1-mediated Ca2+mobilization in endothelial or cancer cells. Fl
PHB antibodies or control IgGs (10 μg/ml). Ca2+mobilization downstream of PAR1 activation in
of PHB using anti-PHB antibody. HUVECs and MDA-MB-231 cells were transfected with siRNA
signiﬁcantly decreased. Knockdownof PHB did not affect the Ca2+mobilization induced by PAR1
indicated by the arrows, and the ﬂuorescence was monitored using a ﬂuorescence spectrophoACUGUGAAAUUTT-3′) and the negative control siRNA (siCtrl,
4390843) were both obtained from Qiagen (Valencia, CA, USA).
2.8. Cell invasion and migration assays
In vitro cell invasion assayswere carried out using a Transwell cham-
ber of 6.5 mm diameter and 8.0 μm pore size polycarbonate membrane
(Corning Costar, NY, USA) coated with Matrigel (BD Biosciences, San
Jose, CA, USA). MDA-MB-231 cells were transfected with either Flag-
PHB1 or empty vector (pCMV-myc). After being starved for 12 h with
a serum free medium, cells were dissociated and added into each
upper chamber of the Transwell chamber, while the bottom chamber
contained a medium with 20 μM PAR1-AP incubated for 24 h at 37 °C.
The invaded cells were dyedwith crystal violet and countedmicroscop-
ically. Three ﬁelds were counted for each assay.
To measure cell migration, after transfection and starvation, cells
were seeded onto Transwell Chambers (8.0 μm pores) (Corning Costar,
NY, USA) coatedwith collagen type I. After 30min, cellswere stimulated
with 20 μM PAR1-AP and incubated for 16 h at 37 °C. Migrated cells
were then dyed with crystal violet. Bound crystal violet was eluted
with 1 ml 10% acetic acid and the migration activity was expressed as
the value monitored at 586 nm of extraction.
2.9. Erk1/2 phosphorylation assay
The Erk1/2 phosphorylation assay was conducted as described pre-
viously [23]. For the internalization inhibitory assay, after HUVECsuo 3-AM-loaded cells were pretreatedwith IV.3 (10 μg/ml) andwere incubated with anti-
human endothelial cells (A) andMDA-MB-231 cells (C) were not affected by the blockade
targeted against PHB, and 48 h after RNAi, Western blot showed that PHB expression was
-APin theHUVECs (B) orMDA-MB-231 cells (D). PAR1-AP (20 μM)was added at the times
tometer.
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ulated with 75 μM PAR1-AP for the indicated times at 37 °C.
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HUVECs by Western blotting
The isolation of plasmamembraneswas done according to amodiﬁca-
tion to themethod described byWahn Soo Choi et al. [24]. Cells (2 × 107)
were homogenated for 30 cycles in 0.25 M sucrose in 20 mM Tris-Hepes
(pH 7.4) and centrifuged (3000 ×g, 10 min). A stepwise sucrose gradient
was created by the sequential addition to centrifuge tubes of 1.6 ml of
40%, 0.8 ml of 15%, and 1.3 ml of 11.5% (w/v) sucrose solution, and ﬁnally
the homogenated cell lysate. After ultracentrifugation at 27,000 g for 3 h
at 4 °C, the middle opaque fractions (plasma membrane fraction) were
collected. The isolations ofmitochondria and nucleuswere done in accor-
dance with the isolation kit protocols. After isolation of the cells' plasma
membrane, mitochondria and nucleus, protein concentrations were de-
termined using a protein assay. The cell fractions (30 μg of protein)
were loaded on an SDS-PAGE gel, and following electrophoresis, electro-
transferred onto a PVDF membrane that was subsequently blocked with
3% BSA and incubated with the appropriate primary and secondary anti-
bodies. Resulting protein bands were visualized using an enhanced
chemiluminescence reagent (Thermo-Fisher).
2.11. Statistical analysis
Each experiment included three to four replicates, and the results
were analyzed using Prism 5.0. Statistical analysis included two-way
ANOVAwith Bonferroni correction and Student's t-tests. All experimen-
tal values are expressed as themeans± SD, with P b 0.05 being consid-
ered statistically signiﬁcant.
3. Results
3.1. PHB does not affect PAR1-mediated Ca2+mobilization in endothelial or
cancer cells.
In our previous work, we found that PHB was a novel cofactor in
PAR1-related signaling activation inhuman platelets. Unfortunately,
these ﬁndings were somewhat limited because of anucleate human
platelets. So we examined the speciﬁc role of PHB in the PAR1 signaling
pathway in nucleated cells, including human endothelial cells
(HUVECs) and highly invasive cancer cells (MDA-MB-231), that express
endogenous PHB and PAR1. Accordingly, we investigated the effects of
PHB on Ca2+ mobilization stimulated by PAR1-AP in these two cell
types. Blocking PHB with an anti-PHB antibody or depletion PHB by
RNAi did not affect the Ca2+ mobilization induced by 20 μM PAR1-AP
in either HUVECs (Fig. 1A, B) or MDA-MB-231 cells (Fig. 1C, D). Like-
wise, treatment of cells with selective siRNA against PHB signiﬁcantly
decreased the expression of PHB in both HUVECs and MDA-MB-231
cells, as determined byWestern blotting (Fig. 1B, D). These results indi-
cate that PHB is not involved in PAR1-mediated Ca2+ mobilization in
endothelial and cancer cells, indicating that PHB plays a different role
here than it does with human platelets.
3.2. Colocalization of PHB and PAR1 is dynamic and is dependent on the
duration of agonist activation in endothelial and cancer cells
While the cellular localization of PHB is very important for its func-
tion, for example, membrane PHB could be a receptor or a cofactor to
regulate the cell signaling pathway [4], and the function of PHB in theFig. 2. Colocalization of PHB and PAR1 is a dynamic process dependent on the duration of agon
expressed on the cell surface inHUVECs. (B) InMDA-MB-231 cells, only PAR1was expressed on
PHB, anti-actin, anti-ﬂotillin (a membrane marker), anti-Histone H3 (a nuclear marker) and an
colocalization strengthened at 15 min and weakened at 120 min when activated with agonist.
MB-231 cells, PHB and PAR1 colocalized at 120min after induction with PAR1-AP, and no coloc
PHB in HUVECs and MDA-MB-231 cells were conﬁrmed by co-immunoprecipitation. Bar, 15 μmregulation of PAR1 is unclear in HUVECs and MDA-MB-231 cells. In
the present study, ﬂow cytometry showed that PHB and PAR1 were
expressed on the surface of HUVECs (Fig. 2A), but in MDA-MB-231
cells, PAR1was expressed on the cell membrane and PHBwas not local-
ized on the cell surface (Fig. 2B).Westernblot also showed that PHBwas
presented on the plasmamembrane of HUVECs but was hardly found in
MDA-MB-231 cells. Total PHB expression inMDA-MB-231was likewise
higher than that in HUVEC, especially in mitochondria and nuclear
(Fig. 2C). Confocal microscopy revealed that PHB colocalized with
PAR1 in the rest (0 min) HUVECs. This colocalization was strengthened
when the cells were activated with PAR1-AP for 15 min but weakened
after 120 min (Fig. 2D). However, in the MDA-MB-231 cells, PHB and
PAR1 colocalized with each other in cells that were activated with
PAR1-AP for 120 min, but not in unactivated or short-term activated
cells (Fig. 2E). Therewas nodifference in cells incubatedwith no agonist
(Fig. 2D, E).
Co-immunoprecipitation assays yielded the same results. PHB and
PAR1 could interact with each other when cells had been activated
with PAR1 activated at 15 min (HUVECs) or 120 min (MDA-MB-231
cells) (Fig. 2F, G). These results revealed that PHB and PAR1 colocalized
in a dynamic process dependent on the length of time following activa-
tionwith PAR1-AP. Additionally, the colocalization of PHB and PAR1 dif-
fers between endothelial and cancer cells, suggesting that PHB may
regulate PAR1 function differently among these different types of cell.
3.3. PHB participates in PAR1 activated internalization and Erk1/2 signal-
ing, but not constitutive internalization, in endothelial cells
To determine the function of PHB in PAR1 trafﬁcking, we depleted en-
dogenous PHB in human endothelial cells (HUVECs) using a speciﬁc
siRNA (siPHB). Confocalmicroscopy showed that constitutive internaliza-
tion of PAR1 was not affected in the siPHB-transfected HUVECs (Fig. 3A),
and a further ELISA showed that there was no difference in PAR1 consti-
tutive internalization between the cells transfected with the control
siRNA or the PHB siRNA in HUVECs (Fig. S1). Interestingly though, PAR1
activated internalization was signiﬁcantly decreased when PHB was
knocked down by siRNAs against PHB as compared with HUVECs
transfected with control siRNAs. Confocal microscopy revealed that the
colocalization of PAR1 and EEA1 (Early EndosomeAntigen 1), an early en-
dosomemarker [25], was signiﬁcantly decreased, and a fraction of the ac-
tivated PAR1 did not internalize and sort to the early endosome in PHB
knockdown cells (Fig. 3B, lower panel). ELISA showed that knockdown
of PHB inhibited PAR1-AP-induced internalization of activated PAR1,
which was highly signiﬁcant at 15 min (inhibited 55.6% compared con-
trol) (Fig. 3C). Additionally, in the HUVECs, PAR1-AP-induced phosphory-
lation of Erk1/2 was affected by PHB depletion. Erk1/2 phosphorylation
was sustained for 15 min in endothelial cells transfected with PHB
siRNA, whereas Erk1/2 phosphorylation in the cells transfectedwith con-
trol siRNA was only sustained for 5 min following PAR1-AP induction
(Fig. 3D).
3.4. PHB does not regulate PAR1 activated internalization or Erk1/2 signal-
ing in breast cancer cells
MDA-MB-231 cells were incubatedwith an anti-PAR1 antibody for 1
h at 4 °C, then were washed and treated with PAR1-AP for 30 min at
37 °C, processed, and ﬁnally examined using a confocal microscope.
After stimulation with PAR1-AP for 30 min, a fraction of the activatedist (PAR1-AP) activation. (A) Based on ﬂow cytometry analysis, both PHB and PAR1 were
the cell surface but not PHB. (C) Total cell lysates and cell fractionswere blottedwith anti-
ti-COXIV (amitochondria marker). (D) In the rest HUVECs, PHB and PAR1 colocalized. The
However, there was no difference within cells incubated with no agonist. (E) In the MDA-
alization in cells incubatedwith on agonist. (F, G) Dynamic interactions between PAR1 and
.
Fig. 3. PHB regulated Erk1/2 signaling and PAR1 activated internalization but not PAR1 constitutive internalization in HUVECs. (A) Constitutive PAR1 internalization was not affected by
PHB knockdown. PAR1 (red), EEA1 (green) and PHB (gray). The colocalization of PAR1 and EEA1 is shown in yellow. (B) Knockdown of PHB inhibited activated PAR1 internalization ac-
cording to confocal microscopy analysis. PAR1 (red), EEA1 (green) and PHB (gray).The colocalization of PAR1 and EEA1 is shown in yellow. When the cells were transfected with PHB
siRNA, a fraction of the PAR1 protein did not colocalize with EEA1, as shown by the red arrow (lower panel). (C) Knockdown of PHB inhibited PAR1 activated internalization as shown
by ELISA. (D) Depletion of PHB prolonged the phosphorylation of Erk1/2 in HUVECs induced with PAR1-AP. The total Erk1/2 served as a loading control. Bar, 15 μm.
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nor did PHB colocalize with PAR1 (Fig. 4A). To further characterize the
potential role of PHB in the PAR1 activated internalization in the
MDA-MB-231 cells, we transfected these cells with PHB siRNA and
using an ELISA found that depletion of PHB did not affect the activated
internalization of PAR1 induced by PAR1-AP (Fig. 4B). By contrast,
when we overexpressed Flag-tagged PHB in the MDA-MB-231 cells,
PAR1 activated internalization was increased 33.1% as compared with
cells transfected with the pCMV-Myc vector, the expression of Flag-
tagged PHB was determined by Western blotting (Fig. 4D) and detec-
tion of the surface expression of PHBwas determined by ﬂowcytometry
(Fig. S2). Further testing of Erk1/2 phosphorylation in MDA-MB-231
cells showed that depletion of PHB did not affect Erk1/2 phosphoryla-
tion (Fig. 4C), and that overexpresion of Flag-tagged PHB shortened
the duration of Erk1/2 phosphorylation to 30 min, nearly half the time
observed in the cells transfected with the pCMV-Myc vector (60 min)
(Fig. 4E). Interestingly, overexpression of Flag-tagged PHB could reduce
both cell invasion (26.86%) and cell migration (19.27%) stimulated by
PAR1-AP as compared with the cell transfected with the empty vector
(Fig. 4F).3.5. PHB negatively regulates the degradation of PAR1 in endothelial and
cancer cells
To examine the effects of PHB on PAR1 degradation, cells were incu-
batedwith an anti-PAR1 antibody for 1 h at 4 °C, thenwashed and treat-
ed with PAR1-AP for 120min at 37 °C, processed, and examined using a
confocal microscope. When endothelial cells were treated with PAR1-
AP for 120 min, surface PAR1 was divided into two fractions, one frac-
tion colocalized with PHB, whereas the other colocalized with LAMP1,
a late endosome and lysosome marker. The second fraction of PAR1
was sorted into the lysosome and degraded (Fig. 5A, upper panel). En-
dothelial cells transfected with PHB siRNA showed higher levels of
PAR1 degradation than cells transfected with control siRNA (Fig. 5B).
Similarly, PAR1 degradation level was decreased in endothelial cells
overexpressing Flag-tagged PHB as compared to cells transfected with
the pCMV-Myc vector (Fig. 5C). These results indicate that PHB nega-
tively regulates PAR1 degradation in endothelial cells. In breast cancer
cells, we found that PHB has a similar function. When MDA-MB-231
cells were treated with PAR1-AP for 120 min, PAR1 colocalized with
PHB but not with LAMP1, indicating that PAR1 was not sorted to the
Fig. 4. PHB loses the ability to regulate PAR1 activated internalization and Erk1/2 phosphorylation in MDA-MB-231 cells while the overexpression of PHB restores this function. (A) Ac-
tivated PAR1 did not completely internalize to the early endosome as determined by confocal microscopy. PAR1 (red), EEA1 (green) and PHB (gray).The colocalization of PAR1 and
EEA1 is shown in yellow, and the fraction of PAR1 did not colocalize with EEA1 shown in red and indicated by the red arrows. Bar, 15 μm. (B) Knockdown of PHB did not affect the inter-
nalization of activated PAR1 as determined by an ELISA. (C) Depletion of PHBdid not affect the PAR1-AP-induced phosphorylation of Erk1/2.(D)Overexpression of PHB increased activated
PAR1 internalization.Western blot using anti-Flag antibodyrevealed the expression level of Flag-PHB. (E) Overexpression of PHB shortened the duration of PAR1-AP-induced Erk1/2 phos-
phorylation. (F) Overexpression of PHB reduced the cell invasion (left) and cell migration (right) induced by PAR1-AP.
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of PAR1 degradation were also observed in cells transfected with PHB
siRNA as compared with cells transfected with control siRNA (Fig. 5D).
However, overexpression of PHB had no effect on PAR1 degradation in
MDA-MB-231 cells (Fig. 5E). These results indicate that PHB negatively
regulates PAR1 degradation in both endothelial cells and cancer cells.
4. Discussion
In our present study, we ﬁrst deﬁned a previously unknown role for
PHB in the regulation of PAR1 activated internalization and degradation
in endothelial cells and cancer cells. PHB was necessary for PAR1activated internalization and Erk1/2 phosphorylation, and PHB nega-
tively regulated PAR1 degradation. Furthermore, our ﬁndings showed
that PHBmembrane absence contributes to the high invasivity in highly
malignant breast carcinomaMDA-MB-231 cells. It is universally accept-
ed that a sustained PAR1 signal could be observed in carcinoma cells,
and our ﬁndings proved that membrane PHB absence leads to a null
PAR1 activated internalization then induces the sustained PAR1 signal
in MDA-MB-231 cells and it is consistent with the previous report
[22].We hypothesize that PHB acts as a chaperone in this process to reg-
ulate PAR1 cellular trafﬁcking and sorting; during PAR1 degradation,
PAR1 dissociates from PHB and is sorted to the lysosome, where it is de-
graded. PHB is amember of the SPFH family, a family of proteins that act
Fig. 5. PHB negatively regulates the degradation of PAR1 in HUVECs andMDA-MB-231 cells. (A) PAR1 degradation in HUVECs (upper panel) and MDA-MB-231 cells (lower panel). PAR1
(red), LAMP1 (green) and PHB (gray). The colocalization of PAR1 and LAMP1 is shown in yellow and is highlighted by the yellow arrow (upper panel). The colocalization of PAR1 and PHB
is shown in gray and is highlighted by the gray arrow (upper and lower panel). (B) Knockdown of PHB increased PAR1 degradation inHUVECs. Cells were incubated in the absence (−) or
presence (+) of 75 μΜ PAR1-AP for 120 min at 37 °C. (C) Overexpression of PHB decreased the level of PAR1 degradation in HUVECs. (D) Knockdown of PHB increased the level of PAR1
degradation in MDA-MB-231 cells. (E) Overexpression of PHB had no effect on PAR1 degradation in MDA-MB-231 cells.
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therefore, our ﬁndings are consistent with these features of the PHB
family.
The relationship between the protein PHB and cancer has been ex-
tensively studied, and the extant evidence indicates that the PHB gene
is likely a tumor suppressor, since its 3′-UTR was previously shown to
inhibit cell cycle progression by blocking G1–S transition in breast and
other cancers [29]. PHB levels are elevated in cervical, esophageal, stom-
ach, breast, lung, bladder, thyroid, ovarian, and prostate cancers [7,8].
However, the role of PHB in cell proliferation or tumor suppression re-
mains controversial. Previous evidence showed that the subcellular lo-
calization of PHB affects cell fate, and as such, the role of PHB in
tumorigenesis may be explained by its subcellular localization. In the
present study, we found that PHB is not expressed on the surface of
the highly invasive MDA-MB-231 breast cancer cells; however, it is
expressed on the surface of primary HUVECs and the lowly invasive
MCF-7 breast cancer cells (Fig. S3). In higher invasive cancer cells, the
loss of PHB membrane localization may have resulted in the loss of
PHB-dependent regulation of PAR1 activated internalization and Erk1/
2 phosphorylation. Therefore, we deduced that membrane PHB exerted
this function and the detection of plasma membrane PHB after PHB
overexpression conﬁrmed this hypothesis. Likewise, because PHB may
have lost its regulatory functions in cancer cells, PAR1 should not inter-
nalize and Erk1/2 phosphorylation should be sustained when activated
by PAR1-AP; and these mechanisms may, at some level, be responsible
for the highly invasive nature of these cancer cells.Our results also showed that PHB negatively regulated PAR1 degra-
dation. The role that PHB plays in this function is due to its association
with PAR1 when cells have been activated by PAR1-AP for long time.
In effect, once PHB dissociates from PAR1, PAR1 can be degraded. Previ-
ous work has shown that PAR1 is highly expressed in breast carcinoma
cells and increases in PAR1 expression have been correlated with carci-
noma cell invasiveness [30]. Additionally, recent research revealed that
deregulated PAR1 trafﬁcking leads to constitutive signaling and pro-
motes cellular invasion [22]. MDA-MB-231 is a type of a highly invasive
breast cancer cell with a high level of endogenous PAR1 and PHB ex-
pression. PAR1 activation and signaling are normally observed in this
cell type, and PHB did not affect the Ca2+ mobilization mediated by
PAR1 (Fig.1C, D). PHB is highly expressed in this cell line; however, it
is not expressed on the cell surface. Therefore, we believe that the ma-
jority of PHB is intracellular. When the cancer cells were activated
with the agonist for long time (120 min), the tight interaction between
PHBand PAR1 inhibited PAR1 degradation. Overall, our results indicated
that high intracellular levels of PHB inhibited PAR1 degradation in
MDA-MB-231 cells, leading to persistent, activated PAR1 signaling.
This signaling may be responsible for cancer cell metastasis and
invasion.
Our results also showed that when PAR1 activated internalization
was reduced, Erk1/2 phosphorylationmediated by PAR1was sustained,
and vice versa. Gourlaouen et al. [31] showed that VEGF2R internaliza-
tion was necessary for Erk1/2 phosphorylation. And a mutation in the
YRRL motif of the thrombopoietin receptor greatly reduced receptor
1401Y.-J. Wang et al. / Biochimica et Biophysica Acta 1843 (2014) 1393–1401internalization and prolonged Erk1/2 phosphorylation [32]. Taken to-
gether, these results indicate that receptor activated internalization is
related to Erk1/2 signaling, and we speculate that PAR1 activated inter-
nalization is related to the duration of Erk1/2 activation. In our study,we
found that inhibition of clathrin-mediated endocytosis by sucrose
(0.4M) [33] resulted in a prolonged duration of Erk1/2 phosphorylation
as compared to control (Fig. S4).
In conclusion, results of our analyses characterized for the ﬁrst time
how PHB is involved in PAR1-related activated internalization, Erk1/2
phosphorylation and PAR1 degradation in both human endothelial
and cancer cells. Our results also suggest that the absence of membrane
PHB indeed contributes to the observed high malignancy in breast car-
cinoma cells. These interesting and fascinating ﬁndings provide clues
and evidences for cancer malignant degree classiﬁcation and diagnosis.
These ﬁndings provide novel clues to some of the underlying mecha-
nisms at play in certain cancerous cells invasiveness and proliferation,
and likewise offer evidence that may be useful in developing future re-
ﬁned classiﬁcations and diagnostics of cancer malignancy.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.04.005.
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